Back to Search Start Over

Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines

Authors :
Yongzheng Li
Jiajing Wu
Xiaoyu Xu
Ran An
Xiaoliang Sunney Xie
Rui Shi
Na-Na Zhang
Chuanping Gao
Liyang Song
Yingmin Ma
Ayijiang Yisimayi
Xuemei Li
Yali Bai
Y Cao
Youchun Wang
Tianhe Xiao
Shuo Du
Yangyang Wei
Yifei Zhang
Wenping Ma
Xiang Li
Junyu Xiao
Weiliang Song
Cheng-Feng Qin
Bin Su
Shuo Liu
Jing Wang
Zhiying Zhang
Xiaofeng Li
Tianjiao Yuan
Ronghua Jin
Yingmei Feng
Yang Dou
Yonghong Zhang
Bai Lu
Weijin Huang
Xianghua Guo
Source :
Cell Research
Publication Year :
2021
Publisher :
Springer Science and Business Media LLC, 2021.

Abstract

SARS-CoV-2 variants could induce immune escape by mutations on the receptor-binding domain (RBD) and N-terminal domain (NTD). Here we report the humoral immune response to circulating SARS-CoV-2 variants, such as 501Y.V2 (B.1.351), of the plasma and neutralizing antibodies (NAbs) elicited by CoronaVac (inactivated vaccine), ZF2001 (RBD-subunit vaccine) and natural infection. Among 86 potent NAbs identified by high-throughput single-cell VDJ sequencing of peripheral blood mononuclear cells from vaccinees and convalescents, near half anti-RBD NAbs showed major neutralization reductions against the K417N/E484K/N501Y mutation combination, with E484K being the dominant cause. VH3-53/VH3-66 recurrent antibodies respond differently to RBD variants, and K417N compromises the majority of neutralizing activity through reduced polar contacts with complementarity determining regions. In contrast, the 242–244 deletion (242–244Δ) would abolish most neutralization activity of anti-NTD NAbs by interrupting the conformation of NTD antigenic supersite, indicating a much less diversity of anti-NTD NAbs than anti-RBD NAbs. Plasma of convalescents and CoronaVac vaccinees displayed comparable neutralization reductions against pseudo- and authentic 501Y.V2 variants, mainly caused by E484K/N501Y and 242–244Δ, with the effects being additive. Importantly, RBD-subunit vaccinees exhibit markedly higher tolerance to 501Y.V2 than convalescents, since the elicited anti-RBD NAbs display a high diversity and are unaffected by NTD mutations. Moreover, an extended gap between the third and second doses of ZF2001 leads to better neutralizing activity and tolerance to 501Y.V2 than the standard three-dose administration. Together, these results suggest that the deployment of RBD-vaccines, through a third-dose boost, may be ideal for combating SARS-CoV-2 variants when necessary, especially for those carrying mutations that disrupt the NTD supersite.

Details

ISSN :
17487838 and 10010602
Volume :
31
Database :
OpenAIRE
Journal :
Cell Research
Accession number :
edsair.doi.dedup.....0cc6da328c967b8d310b738c681960ad